News
Market and company headlines
PFEAll
Loading
13:00-16:00Yesterday2 Stories
Pfizer (PFE) Stock Looks Above Fair Value As 30% Run Continues
Pfizer has delivered a solid 1 year return, yet the question many investors are circling is whether that share price now lines up with what its earnings can support. With vaccine headlines and deal activity back in the news, the issue is whether the current valuation fairly reflects the profit engine behind the story. The stock has returned 29.7% over the past year, which puts real pressure on the earnings picture to justify the higher price investors are paying today. Fresh data on Pfizer's...
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
NEW YORK, October 26, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. mAPMN/S is also known as metastatic hormone-sensitive prostate cancer
08:00-10:00Yesterday2 Stories
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Moderna's personalized melanoma vaccine cleared its primary hurdle in a late-stage trial, yet shares are sinking fast. The gap between what the data promised and what it delivered is forcing traders to rethink how much the company's flagship cancer bet is actually worth.
Can Pfizer Stock Get Back To Where It Was?
For questions about this article or underlying research, email help@trefis.com.
22:00Oct 251 Story
11:00-19:00Oct 242 Stories
Pfizer And 2 Other AI Healthcare Stocks To Watch
Warning signs around heavily indebted AI infrastructure firms have grown louder after analysts raised the risk of a tech debt spiral, with some newer players struggling to finance data centers and high-end chips. That strain shifts attention toward more grounded uses of AI that address urgent problems such as healthcare. Investors seeking substance over hype may find this article useful. It profiles three AI powered healthcare stocks from our screener. The three stocks covered below are a...
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
NEW YORK, October 24, 2026--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today
03:00Oct 241 Story
06:00-21:00Oct 232 Stories
Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?
Pfizer (PFE) is back in focus after signing a research collaboration and license agreement with Enodia Therapeutics that gives the drugmaker access to Enodia’s Sec61 inhibitor programs for potential oncology and specialty treatments. Pfizer’s agreement with Enodia lands at a time when momentum in the shares has been rebuilding, with a 30 day share price return of 6.56% and a 90 day gain of 22.37%. The 1 year total shareholder return of 29.79% contrasts with a weaker 5 year total shareholder...
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
One of these pharma stocks offers more income, but the other offers a safer dividend.
12:00-18:00Oct 222 Stories
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.
Pfizer’s High Dividend Yield May Be a Warning. Here’s How Merck Compares
Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a very different story.
00:00Oct 221 Story
16:00-23:00Oct 202 Stories
What Have Pfizer Stock Holders Really Earned?
The dividend is probably the reason investors hold Pfizer (PFE), the maker of medicines such as Eliquis and Padcev. The stock yielded 5.8% at the October 19, 2026 close. Over the past five years, though, the share price has fallen far behind the S&P 500. So take a guess: once every dividend is counted, how did five years of owning Pfizer turn out next to the market.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day.
08:00-14:00Oct 202 Stories
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%
Moderna stock is surging ahead of a closely watched cancer data readout in Madrid, and the stakes could not be higher for a company with nearly $800 million in quarterly losses and no approved cancer product yet.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
17:00-23:00Oct 192 Stories
What Pfizer Bulls Got Right
Pfizer spent 2026 stacking cancer headlines, from fresh breast cancer approvals to a multibillion dollar oncology alliance, even as quarterly profit swung from a US$2,885 million gain to a loss and net margin moved from 19.7% to 1.7% in the red. Investors who held Pfizer from the start of the year saw a 23.0% return, including dividends. If you were weighing a buy on 1 January, what needed to look credible about this reinvention story to take that risk? A Narrative on Simply Wall St is one...
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?
The stock has outperformed the market this year, and it still looks heavily undervalued.
09:00-12:00Oct 193 Stories
Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest.
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger. That sounds like an easy valuation story until the profit figures enter the picture. Bristol Myers reported a 40% rise in second-quarter adjusted earnings per share, while Pfizer’s adjusted earnings were virtually unchanged. But those […]
12:00Oct 171 Story
11:00-16:00Oct 162 Stories
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.
What to Expect From Pfizer's Q3 2026 Earnings Report
Pfizer will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.
00:00Oct 161 Story
12:00-16:00Oct 152 Stories
Better Dividend Stock: Pfizer vs. GSK
Key TakeawaysPfizer yields 6. 3% and GSK yields 4.
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.
03:00Oct 151 Story
16:00-00:00Oct 142 Stories
Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today?
Insider purchases, a multibillion-dollar acquisition and progress in vaccine research helped drive interest.
Pfizer (PFE) Gains As Market Dips: What You Should Know
The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.
15:00Oct 141 Story
10:00-18:00Oct 42 Stories
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield
The crowd is looking at the next couple of years. It should be looking five years into the future.
11:00-13:00Oct 23 Stories
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.
Pfizer’s Eczema Drug Hit a 61% Response Rate the Day Florida Sued. Here’s What It Means for the Stock
Key Stats for Pfizer StockCurrent Price: $28. 12Street Target (Mean): ~$29Next Earnings: November 3, 2026What Happened?Florida’s attorney general sued Pfizer (PFE:NYSE) and CEO Albert Bourla on Thursday, October 1, alleging the company misled consumers about its COVID-19 vaccine.
06:00-08:00Oct 22 Stories
Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency
Pfizer Inc. (NYSE:PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.In the two
How Has Pfizer's Story Changed?
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.
04:00Oct 21 Story
11:00Sep 302 Stories
PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer
Key TakeawaysPfizer yields about 6% and Bristol Myers about 4%, and each has more than $22 billion of revenue from drugs losing U. S.
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.
09:00Sep 301 Story
09:00-17:00Sep 292 Stories
With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap?
While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.
07:00Sep 291 Story
08:00-11:00Sep 242 Stories
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
05:00-07:00Sep 242 Stories
Pharmaceutical Drug Delivery Market Forecasts Growth from $2.15T (2026) to $2.92T by 2031, Profiling J&J, Pfizer, Roche, BD & Novartis
The global pharmaceutical drug delivery market is projected to grow from USD 2.15 trillion in 2026 to USD 2.92 trillion by 2031, registering a 6.3% CAGR. Growth is driven by rising chronic disease prevalence, biologics, biosimilars, advanced therapies, self-administration and connected drug-device technologies. Injectable drug delivery led the market in 2025, while hospitals were the largest facility segment. North America dominated due to advanced healthcare infrastructure, strong R&D and wides
Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks
Pfizer (PFE) scores 9/10 on ChartMill Technical and Setup Quality ratings, signaling a strong trend with a tight breakout setup.
11:00-13:00Sep 232 Stories
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
05:00-11:00Sep 232 Stories
Pfizer’s International Chief Just Explained How the Turnaround Actually Works. Here’s Where the Stock Could Go
Key Stats for Pfizer StockCurrent Price: $27. 93Target Price (Mid): ~$29Street Target: ~$29Potential Total Return: ~5%Annualized IRR: ~1.
Pfizer (PFE) Stock May Be Overvalued After Overseas Pricing Deal
Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the question is how much of the latest news and revenue mix shifts are already reflected in that figure. The 23.9% 1 year return has reset expectations for Pfizer, which puts more weight on whether its earnings base can carry that higher price level. Fresh...
04:00Sep 231 Story
12:00-18:00Sep 222 Stories
Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade)
Pfizer delivered a Q2 double beat, raised full-year revenue guidance, and benefits from pipeline progress. Read why PFE stock is a Buy.
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.